Assessment of Cancer Concerns at the End of Treatment (ACE)
Overview
This study will describe patient-reported symptom burden and concerns, quality of life (QOL), and health behaviors of breast cancer(BC) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate provider satisfaction following delivery of an electronic health record (HER)/EPIC summary of these PROs. Secondary aims will estimate differences in referral to available services between those providers exposed to the PRO summary and historical controls. BC survivors who have completed initial treatment and present within the first year following treatment for an end of treatment (EOT)/survivorship focused visit will be the focus of this study.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: January 19, 2018
Interventions
- Behavioral: Questionnaire
Clinical Trial Outcome Measures
Primary Measures
- Completion of Questionnaire
- Time Frame: 2 years
Participating in This Clinical Trial
Inclusion Criteria
1. Diagnosed with invasive, non-metastatic BC (Stage I, II, or III) without hematogenous or distant metastases 2. Have completed initial treatment (chemotherapy, radiotherapy, and/or surgery). May still be receiving hormonal or targeted therapy (e.g., tamoxifen, aromatase inhibitors). 3. Within 1 year of completing primary treatment 4. Scheduled for an EOT visit 5. Age 18 years or older 6. Can understand written English 7. Have internet access and a working email address Exclusion Criteria:
1. Diagnosed with non-invasive (Stage 0/DCIS) or metastatic (Stage IV) cancer or hematogenous or distant metastatic disease 2. No working email address -
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Linda Jacobs, CRNP, PhD, Principal Investigator, Abramson Cancer Center at Penn Medicine
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.